Biorasi Appoints Melissa Alesse as President as Chris O’Brien Moves to Board Role

• Biorasi, LLC has appointed Melissa Alesse as President, with Chris O’Brien transitioning to a role on the company’s Board of Directors. 

• The leadership change is part of the company’s ongoing organizational evolution as it continues to expand its clinical development operations. 

Biorasi, LLC has appointed Melissa Alesse as President, marking a leadership transition within the contract research organization (CRO). Chris O’Brien, who previously served in a leadership role, will move to the company’s Board of Directors. 

The appointment places Alesse in charge of overseeing the company’s operations as it continues to scale its clinical development services. The transition follows her recent role as Chief Operating Officer, where she was responsible for clinical operations and delivery functions. 

Biorasi said the leadership change is intended to support its next phase of growth, with O’Brien remaining involved at the board level. The company provides clinical research services to pharmaceutical and biotechnology clients, positioning itself within the global CRO market. 

The announcement reflects an internal succession plan, with Alesse taking on expanded responsibilities while maintaining continuity in the company’s strategic direction. O’Brien’s move to the board is expected to provide ongoing oversight and guidance as the organization develops its clinical trial capabilities. 

“Melissa Alesse appointed President as Chris O’Brien steps into Board of Directors role”

Biorasi’s official announcement